• Heber D, Fair W, Ornish D. Capcure (1999). Nutrition & Prostate Cáncer: A Monograph from the CaP CURE Nutrition Project. 2nd edition. January http://www. capcure. org.il/abs tracts/pub- pdf/nutrit ion.pdf.
• Heby O. Role of polyamines in the control of cell proliferation and differentiation. Different 19(1):1-20, 1981
• Heinonen O, Albanes D, Virtamo J. Prostate cáncer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. Journal National Cáncer Institute 90:440-446,1998
• Helpap B, Bostwick D, Montironi R. The significance of atypical adenomatous hyperplasía and prostatic intraepithelial neoplasía for the development of prostate carcinoma. An Update. Virchows Arch.426(5): 425-34, 1995
• Hennenfent BR. The economics of urological care in the 21st century (letter). Urology 47:285-286, 1996
• Hebert J, Hurley T, Olendzki B et al. Nutritional and socioeconomic factors in relation to prostate cáncer mortality: a cross-national study. J Natl Cáncer Inst. 90(21):1637-47, Nov 4 1998
• Heimendinger J, Van Duyn M. Dietary behavior change: the challenge of recasting the role of fruit and vegetables in the American diet. Am J Clin Nutr 1995;61:1397S-13401S
• Hernandez J, Basler J, Thompson I. The potential role of ciclooxygenase-2 inhibitors and 5-alfa reductasa inhibitors in the prevention of urologic conditions. Urol Clin N Am 31(2):213-218, Mayo 2004.
• Hernandez J, Syed S, Thompson I et al. The modulation of prostate cáncer risk with alpha-tocopherol: a pilot randomized, controlled trial. J Urol. 174(2):519-522, Aug 2005
• Hiatt R, Armstrong M, Klastski A. Alcohol consumption, smoking and other risk factors and prostate cáncer in a large health plan cohort in California (United States) Cáncer Causes Control 5:66-72,1994
• Higgins B, Thompson I. The prostate cáncer prevention trial: current status. J Urol 171 (2) part 2 of 2: S15-S18, Feb 2004
• Hill P, Wynder E, Garbaczewski L. Diet and urinary steroids in black and white North American men and black South African men. Cáncer Research 39(12): 5101-5105, 1979.
• Hochberg D, Basíllote J, Armenakas N et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasía. J Urol 167: 1731–1733, 2002
• Hood L, Belldegrun A, Lamb D, et al. The coming revolution in Urology. Contemp Urol 9(6):33-52. Jun 1997
• Hodek P, Trefil P, Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chemico-Biological Interactions 139:1:1–21, 2002
• Hoenjet K et al. Effect of a nutritional supplement containing vitamin E, Selenium, Vitamin C and Coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: A randomized placebo-controlled study. Eur Urol 47:433-440, 2005
• Hong S, Kim S,Kwon S et al. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasía. Yonsei Med J. 43(2):236-41, April 2002
• Hongmei A, Jingnan B. Curative effect analysis of 122 tumor patients treated by the intelligence Qi Gonog, Second World Conference on Academic Exchange of Medical Qigong Sep 15,1993
• Hsieh L, Carter H, Landis P et al. Association of energy intake with prostate cáncer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 61(2):297-301, Feb 2003
• Hsieh T, Lu X, Chea J et al. Prevention and management of prostate cáncer using PC-SPES: a scientific perspective. J Nutr. 132(11 Suppl):3513S-3517S, Nov 2002
• Hsing A et al. Tobacco Use and Prostate Cáncer: 26 years follow-up of US Veterans. Am J Epidemiol 133:437-441, 1991
• Hsing A, Comstock G, Abbey H. Serologic precursors of cáncer: retinol, carotenoids, and tocopherol and risk of prostate cáncer. Journal of the National Cáncer Institute 82(11): 941-946, 1990.
• Hughes-Fulford M, Chen Y, Tjandrawinata R. Fatty acid regulates gene expression and growth of human prostate cáncer PC-3 cells. Carcinogenesis. 22(5):701-707, May 2001
• Huggins C, Hodges C. Studies on prostate cáncer; effect of castration. estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cáncer Res 1:293-297,1941
• Ianucci M et al. Chemoprevention in chronic prostatitis, in BPH and in low grade carcinoma. Europ Urology Today 16 (4) Dec 2004
• Iczkowski K, Qiu J, Qian J et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cáncer volume in human prostate. Urology. 65(1):76-82, Jan 2005
• Imaida K, Tamano S, Kato K et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 22:467-472, March 2001
• Imperato-McGinley J, Gautier T, Zirinsky K. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. Journal of Clinical Endocrinology and Metabolism 75(4): 1022-1026, 1992.
• Irwin N President American Urological Association 2000 http://www. auanet.or g/advocacy/ne ws/fda/f oodSup sp00.cfm) May 2000.
• Isaacs J. Hormonal balance and the risk of prostatic cáncer. J Cell Biochemistry 16H(suppl): 107-108, 1992.
• Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasía: A systematic review and quantitative meta-analysis Am J Med 109:654-664,2000.
• Israel K, Sanders B, Kline K. Alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutrition and Cáncer 24(2): 161-169, 1995.
• Istfan N, Person K, Holick M et al. 1-alpha,25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cáncer cells.J Steroid Biochem Mol Biol 103(3-5):726-730, Mar 2007
• Jacobs M. Effects of selenium on chemical carcinogens. Preventive Medicine 9(3): 362-367, 1980.
• Jacobs J. Unproven alternative methods of cáncer treatment. In Cáncer: Principles and Practice of Oncology (5th edition). Eds Devita V, Hellman S, Rosenberg S : 2993-3001. Philadelphia Lippincott-Raven
• Jacobsen et al. Does high soy milk intake reduce prostate cáncer incidence? The Adv Health Stud Canc Caus Cont 9:553-557,1998
• Jain M et al. Plant foods antioxidants, and prostate cáncer risk: findings from case-control studies in Canada. Nutrit and Canc 34(2):173-84, 1999.
• Jankun J et al. Why drinkinggreen tea could prevent cáncer. Nature 387:561, 1997
• Jemal A, Siegel R, Ward E et al. Cáncer statistics. Cáncer J Clin. 57(1):43-66, Jan-Feb 2007
• Jenkins D, Kendall C, D´Costa M, et al. Soy consumptiom and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol 169(2): 507-511 Feb 2003
• Jeong DH, Park YI. Clinical Experience of Symptomatic Management of BPH with Terazosin, Doxazosin or Combination of Terazosin and Finasteride. Korean J Urol. 39(8):772-776, Aug 1998
• Jian L, Ping Xie L, Lee A, et al. Protective effect of green tea against prostate cáncer: A case-control study in southeast China. International Journal of Cáncer. 108(1):130–135, Oct 2003
• Jiang Q, Christen S, Shigenaga M et al.{gamma}-Tocopherol, the major form of vitamin E in the US diet, deserves more attention 1,2,3. American Journal of Clinical Nutrition 74(6): 714-722, Dec 2001
• John E, Dreon D, Koo J et al. Residential sunlight exposure is associated with a decreased risk of prostate cáncer. J Steroid Biochem Mol Biol. 89-90(1-5):549-552, May 2004
• John E, Schwartz G, Koo J et al. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cáncer. Cáncer Res. 65(12):5470-5479, 15 Jun 2005
• Joniau S, Goeman L, Roskams T, et al. The effect of chemoprevention on PSA and clinical management in patients with high grade prostatic intraepithelial neoplasía. Eur Urol supplm abstract # 259 3:67,2004
• Kadmon D, Thompson I. Chemoprevention in Prostate Cáncer. Ch 39: 657-667.Comprehensive textbook of genitourinary oncology. Eds Vogelzang N, Scardino P, Shipley W, Coffey D.Williams&Wilkins 1996.
• Kao G et al. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cáncer 88 (3): 615-619, 2000.
• Kaplan S, Ghafar M, Volpe M et al. PSA response to finasteride challenge in men with serum PSA greater than 4 ng/ml and previous negative prostate biopsy: a preliminary study Urology 60(3):464-468, Sept 2002.
• Kaplan S, Volpe M, Te A. A prospective 1-year trial using Saw palmetto versus Finasteride in the treatment of category III Prostatitis/chronic pelvic pain syndrome. J Urol 171(1): 284-288, Jan 2004.
• Kaplan S et al. Practical Guidelines for the Treatment of Enlarged Prostate in the Primary Care Setting. http://www. medscape. com/ view article/ 505863_1, June 17, 2005. The Center for Medical Knowledge, In Medscape Today.
• Kaplan SA. Benign Prostatic Hyperplasía. Journal of Urology 176(3): 1061-1063, September 2006
• Kaplan S, Holtgrewe H, Bruskewitz R et al. Proscar Long-Term Efficacy and Safety Study Group (PLESS) Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasía. Urology 57(6):1073-1077, Jun 2001
• Kassen A, Berges R, Senge T. Effect of beta-sitosterol on transforming growth factor-beta-1 expression and translocation protein kinase C alpha in human prostate stromal cells in vitro. Eur Urol. 37(6):735-741, Jun 2000
• Katske F et al. Treatment of Insterstitial Cystitis with a Quercetin Supplement. Techniques in Urology 7(1): 1-3,March 2001
• Katz I, Sands L, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46: 8-13, 1998
• Katz A. Flavonoid and botanical approaches to prostate health. J Altern Complem Med. 8(6):813-821, Dec 2002
• Keetch D, Humphrey P, Stahl D, et al. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasía in needle biopsy of the prostate. J Urol 154(2Pt1): 347-51, Aug 1995.
• Keledjian K et al. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48(2):71-8, 1 Jul 2001
• Keledjian K, Garrison J, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasíon. J Cell Biochem 94(2):374-388, 1 Feb 2005
• Kelloff G et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cáncer chemoprevention. Cáncer Epid Biom Prev 5:657-66, Aug 1996
• Kelloff G et al. Aromatase inhibitors as potential cáncer chemopreventives. Cáncer Epidemiol Biomarkers Prev 7:65-78, Jan 1998
• Kelloff G, Lieberman R, Steele V, et al. Chemoprevention of prostate cáncer: concepts and strategies Eur Urol 35:342-350, 1999
• Kelloff G et al. Introductory remarks development of chemopreventive agents for prostate cáncer. J Cell Bioc Suppl 16:1-8, 1992